Getting the Dose Right in Drug Development for Rare Diseases: Barriers and Enablers

Area of Science:

• Drug Development
• Clinical Pharmacology
• Rare Diseases

Background:

• Dose-finding studies are crucial for drug development and registration trials.
• Rare diseases present unique challenges including poorly understood pathophysiology, limited models, and small patient populations.
• Heterogeneity and defining endpoints further complicate data utilization in rare disease research.

Purpose of the Study:

• To explore critical dose selection aspects in drug development for rare diseases.
• To address challenges in therapeutic areas like oncology, neurology, hepatology, and metabolic rare diseases.
• To examine dose selection for pediatric rare diseases and novel therapeutic modalities.

Main Methods:

• Review of dose selection challenges in rare disease drug development.
• Focus on key therapeutic areas and emerging treatment modalities.
• Emphasis on the role of clinical pharmacology.

Main Results:

• Rare diseases pose significant hurdles in dose-finding studies due to limited data and patient populations.
• Pediatric rare diseases and novel therapies like gene therapy require specialized dose selection strategies.
• Clinical pharmacology plays a pivotal role in overcoming these complexities.

Conclusions:

• Effective dose selection in rare diseases requires tailored strategies and robust clinical pharmacology.
• Addressing the unique challenges of rare diseases is essential for successful drug development.
• Novel therapeutic modalities necessitate careful consideration in dose determination.